Microfluidic Biosensor Using C. elegans for Metastasis Detection

The patent introduces an intermediary detection system using microfluidic devices and optical imaging to bridge the gap between complex conventional diagnostics and simple point-of-care testing. The microfluidic chip acts as a mediator that processes biological samples and translates complex biochemical information into observable optical signals that can be captured by standard imaging devices, thereby achieving high measurement precision without requiring specialized medical equipment.

The patent creates a simplified copy of the complex diagnostic process by using microfabricated structures that replicate key functions of MRI and CT scanners at a miniature scale. The microfluidic channels and chambers are designed to mimic the separation and analysis functions of conventional diagnostic equipment, but in a compact, portable format that can be operated without specialized training.

The microfluidic device is designed to perform sample processing, analysis, and result generation automatically without requiring user intervention for complex operations. The device self-regulates fluid flow through pressure gradients, automatically separates analytes, and generates readable outputs, enabling patients or non-specialist healthcare workers to perform metastatic status testing independently at point-of-care settings.

The patent replaces complex mechanical and manual operations of conventional diagnostics with automated microfluidic systems and optical detection. Instead of requiring manual tissue sectioning, staining, and microscopic examination by trained pathologists, the system uses pressure-driven fluid flow and optical imaging to automatically process samples and generate diagnostic information that can be interpreted by non-experts.

The microfluidic device performs preliminary separation and concentration of target analytes before final detection, pre-processing the sample in a way that enhances signal strength and reduces background interference. This preliminary action ensures that even rapid detection methods maintain high measurement precision by concentrating the analytes of interest in specific chambers where they can be detected with high sensitivity.

The system optimizes detection parameters such as pressure gradients, flow rates, and optical detection settings to achieve both rapid assessment and high precision. By carefully controlling these parameters, the device maintains measurement accuracy while reducing analysis time, allowing metastatic status to be determined quickly without sacrificing diagnostic reliability.